gdc-0449 and Chondrosarcoma

gdc-0449 has been researched along with Chondrosarcoma* in 2 studies

Reviews

1 review(s) available for gdc-0449 and Chondrosarcoma

ArticleYear
Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma.
    Pharmacology & therapeutics, 2012, Volume: 136, Issue:2

    The hedgehog signaling pathway is important in embryogenesis and post natal development. Constitutive activation of the pathway due to mutation of pathway components occurs in ~25% of medulloblastomas and also in basal cell carcinomas. In many other malignancies the therapeutic role for hedgehog inhibition though intriguing, based on preclinical data, is far from assured. Hedgehog inhibition is not an established part of the treatment paradigm of sarcoma but the scientific rationale for a possible benefit is compelling. In chondrosarcoma there is evidence of hedgehog pathway activation and an ontologic comparison between growth plate chondrocyte differentiation and different chondrosarcoma subtypes. Immunostaining epiphyseal growth plate for Indian hedgehog is particularly positive in the zone of pre-hypertrophic chondrocytes which correlates ontologically with conventional chondrosarcoma. In Ewing sarcoma/PNET tumors the Gli1 transcription factor is a direct target of the EWS-FLI1 oncoprotein present in 85% of cases. In many cases of rhabdomyosarcomas there is increased expression of Gli1 (Ragazzini et al., 2004). Additionally, a third of embryonal rhabdomyosarcomas have loss of Chr.9q22 that encompasses the patched locus (Bridge et al., 2000). The potential to treat osteosarcoma by inhibition of Gli2 and the role of the pathway in ovarian fibromas and other connective tissue tumors is also discussed (Nagao et al., 2011; Hirotsu et al., 2010). Emergence of acquired secondary resistance to targeted therapeutics is an important issue that is also relevant to hedgehog inhibition. In this context secondary resistance of medulloblastomas to treatment with a smoothened antagonist in two tumor mouse models is examined.

    Topics: Anilides; Animals; Apoptosis; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Chondrosarcoma; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Medulloblastoma; Mesenchymal Stem Cells; Osteosarcoma; Pyridines; Sarcoma; Signal Transduction; Zinc Finger Protein Gli2

2012

Trials

1 trial(s) available for gdc-0449 and Chondrosarcoma

ArticleYear
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11

    Pre-clinical data have suggested a therapeutic role of Hedgehog (Hh) pathway inhibitors in chondrosarcoma.. This phase II trial included patients with progressive advanced chondrosarcoma. They received GDC-0449 150 mg/day (days 1-28, 28-day cycle). The primary end point was the 6-month clinical benefit rate (CBR) defined as the proportion of patients with non-progressive disease at 6 months. A 6-month CBR of 40% was considered as a reasonable objective to claim drug efficacy.. Between February 2011 and February 2012, 45 patients were included. Twenty had received prior chemotherapy. Thirty-nine were assessable for efficacy. The 6-month CBR was 25.6% (95% confidence interval 13.0-42.1). All stable patients had grade 1 or 2 conventional chondrosarcoma with documented progression within the 6 months before inclusion. All but one with available data also had overexpression of the Hh ligand. Median progression-free and overall survivals were 3.5 and 12.4 months, respectively. The most frequent adverse events were grade 1 or 2 myalgia, dysgeusia and alopecia.. GDC-0449 did not meet the primary end point of this trial. Results suggest some activity in a subset of patients with progressive grade 1 or 2 conventional chondrosarcoma. Further studies assessing its role in combination with chemotherapy are warranted.. NCT01267955.

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Chondrosarcoma; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; France; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Middle Aged; Pyridines

2013